106 related articles for article (PubMed ID: 10197630)
1. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.
Fujiwara Y; Chi DD; Wang H; Keleman P; Morton DL; Turner R; Hoon DS
Cancer Res; 1999 Apr; 59(7):1567-71. PubMed ID: 10197630
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients.
Taback B; Fujiwara Y; Wang HJ; Foshag LJ; Morton DL; Hoon DS
Cancer Res; 2001 Aug; 61(15):5723-6. PubMed ID: 11479206
[TBL] [Abstract][Full Text] [Related]
3. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
Xu XF; Tang PZ; Cheng SJ
Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
[TBL] [Abstract][Full Text] [Related]
4. [Genetic instability in human malignant uveal melanomas].
Proniewska-Skretek E; Pepiński W; Skawrońska M; Mariak Z; Zalewska R; Janica J; Stankiewicz A
Klin Oczna; 2003; 105(6):401-5. PubMed ID: 15049265
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma.
Goessl C; Heicappell R; Münker R; Anker P; Stroun M; Krause H; Müller M; Miller K
Cancer Res; 1998 Oct; 58(20):4728-32. PubMed ID: 9788629
[TBL] [Abstract][Full Text] [Related]
6. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
Schwarzenbach H; Müller V; Stahmann N; Pantel K
Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.
Pang JZ; Qin LX; Ren N; Hei ZY; Ye QH; Jia WD; Sun BS; Lin GL; Liu DY; Liu YK; Tang ZY
Clin Cancer Res; 2007 Dec; 13(24):7363-9. PubMed ID: 18094418
[TBL] [Abstract][Full Text] [Related]
8. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
9. [Loss of heterozygosity at chromosome 3p14, 25 in serum DNA from ovarian cancer patients].
Zhang H; Li Z; Chen M; Zhang G; Xu K
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):298-300. PubMed ID: 12133406
[TBL] [Abstract][Full Text] [Related]
10. [Minimal commonly deleted regions on chromosome 7q31 in primary gastric carcinoma and its clinical significance].
Li JT; Fu L; Xia JC; Feng BJ; Mai SJ; Yu XJ; Huang LX; Feng QS; Pan ZZ; Zhan YQ
Ai Zheng; 2005 Nov; 24(11):1306-11. PubMed ID: 16552953
[TBL] [Abstract][Full Text] [Related]
11. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
Taback B; Giuliano AE; Hansen NM; Singer FR; Shu S; Hoon DS
Cancer Res; 2003 Apr; 63(8):1884-7. PubMed ID: 12702578
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma.
Ariyanayagam-Baksh SM; Baksh FK; Swalsky PA; Finkelstein SD
Mod Pathol; 2003 Oct; 16(10):992-5. PubMed ID: 14559981
[TBL] [Abstract][Full Text] [Related]
13. Investigation of allelic imbalances on chromosome 3p in nasopharyngeal carcinoma in Tunisia: high frequency of microsatellite instability in patients with early-onset of the disease.
Trimeche M; Braham H; Ziadi S; Amara K; Hachana M; Korbi S
Oral Oncol; 2008 Aug; 44(8):775-83. PubMed ID: 18206419
[TBL] [Abstract][Full Text] [Related]
14. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
[TBL] [Abstract][Full Text] [Related]
16. Detailed deletion mapping of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis.
Xu XF; Gao YN; Cheng SJ
Chin Med J (Engl); 2004 Aug; 117(8):1204-9. PubMed ID: 15361296
[TBL] [Abstract][Full Text] [Related]
17. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
18. Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma.
Lindforss U; Fredholm H; Papadogiannakis N; Gad A; Zetterquist H; Olivecrona H
Cancer; 2000 Jun; 88(12):2661-7. PubMed ID: 10870047
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
20. Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma.
Cheung TH; Chung TK; Poon CS; Hampton GM; Wang VW; Wong YF
Cancer; 1999 Oct; 86(7):1294-8. PubMed ID: 10506716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
